Welcome
Zafgen is an innovative company dedicated to addressing the unmet need of severely obese patients by bringing beloranib, a first-in-class novel medicine, to market.
At Zafgen we bring together leading experts in obesity and metabolic disease to address the underserved and growing population of the severely obese. We are committed to:
- Advancing medicine through treating the biological mechanism of obesity
- Increasing the overall health and quality of life for patients
- Dispelling the stigma that obesity is a "lifestyle choice," not a disease
People who are severely obese are among the most medically underserved populations globally. Obesity is also one of the leading underlying drivers of healthcare costs, pain and suffering among Americans, and the prevalence is increasing.
While diet and exercise are the preferred choice to drive weight loss, many people require therapy to reduce their weight. Zafgen hopes to improve the quality of life of people suffering from obesity through the development and commercialization of beloranib, a novel obesity therapy that utilizes a unique mechanism of action to restore balance to the production and utilization of fat, ultimately returning obese individuals to a lean, healthy body weight.
Science
Zafgen is committed to advancing novel therapeutics for patients suffering from obesity and obesity-related disorders by providing clinicians with powerful new tools. The company's novel therapy, beloranib, demonstrates a unique mechanism of action through inhibition of MetAP2, an enzyme that converts circulating lipids into ketones that can be burned and eliminated from the body.
The Zafgen Team
A growing body of research demonstrates that the nature of adipose tissue, or fat cells, is a significant determinant of obesity. Variations in this tissue - how active or "hungry" it is - affect how much it grows or shrinks in response to dietary intake, and thus whether or not an individual maintains a healthy weight or becomes obese.
Latest News
